Epizyme Company Profile (NASDAQ:EPZM)

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme, Inc. (NASDAQ:EPZM) issued its earnings results on Friday, August, 4th. The company reported ($0.48) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.56) by $0.08. The company had revenue of $10 million for the quarter, compared to the consensus estimate of $3.95 million. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The firm's revenue for the quarter was up 2027.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.49) EPS. View Epizyme's Earnings History.

10 brokerages have issued 12 month price targets for Epizyme's shares. Their forecasts range from $20.00 to $28.00. On average, they expect Epizyme's stock price to reach $24.43 in the next year. View Analyst Ratings for Epizyme.

Here are some recent quotes from research analysts about Epizyme stock:

• 1. According to Zacks Investment Research, "Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. Additionally, its attempts to evaluate tazemetostat in combination with anti-PD 1 or PDL-1 agent are also encouraging. We believe, the  company’s collaboration agreement with Celgene for small-molecule HMT inhibitors including pinometostat is a big positive. Epizyme’s share price has also outperformed the Zacks classified Medical/Biomedical Genetics industry year to date. However, with no approved product in its portfolio, Epizyme is highly dependent on its collaboration partners for top-line growth. Loss estimates have narrowed mostly stable lately ahead of the Q2 results. Epizyme has a positive record of earnings surprises in the recent quarters." (7/18/2017)
• 2. Cann analysts commented, "Epizyme, Inc. announced today that the US Food and Drug Administration has granted Orphan Drug designation to Tazemetostat, for the treatment of patients with soft tissue sarcoma (STS). Management reported they are looking forward to continued engagement with FDA on Tazemetostat for rapid development in both solid tumors and hematological malignancies. Orphan Drug status for Tazemetostat supports our expectation that Epizyme could launch it in 2018. While the company has only guided to a goal of filing Tazemetostat with FDA by early 2018, we anticipate the drug could be approved and launched in the same year, due to the high unmet need in the settings where it is being developed: rare hematologic and solid tumor cancers." (6/21/2017)
• 3. Cowen and Company analysts commented, "Abstracts from ICML further support BGB-3111’s efficacy profile as being superior." (6/7/2017)

Some companies that are related to Epizyme include NovoCure Limited (NVCR), Halozyme Therapeutics (HALO), Radius Health (RDUS), Array BioPharma (ARRY), Lexicon Pharmaceuticals (LXRX), MyoKardia (MYOK), Acceleron Pharma (XLRN), Clinigen Group PLC (CLIN), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR), NeuroDerm (NDRM), Dermira (DERM), Omeros (OMER), Xencor (XNCR), Retrophin (RTRX), Ascendis Pharma A/S (ASND), Dynavax Technologies Corporation (DVAX) and Sangamo Therapeutics (SGMO).

Epizyme's management team includes the folowing people:

• David M. Mott, Independent Chairman of the Board
• Robert B. Bazemore Jr., President, Chief Executive Officer, Director
• Andrew E. Singer, Executive Vice President - Finance and Administration, Chief Financial Officer, and Treasurer
• Matthew Ros, Chief Operating Officer
• Peter T.C. Ho M.D., Ph.D., Executive Vice President, Chief Medical Officer
• Susan E. Graf, Chief Business Officer
• Kevin T. Conroy, Director
• Andrew R. Allen M.D. Ph.D., Independent Director
• Kenneth M. Bate, Independent Director
• Carl S. Goldfischer M.D., Independent Director

Epizyme's stock is owned by a number of of retail and institutional investors. Top institutional investors include NEA Management Company LLC (10.73%), Palo Alto Investors LLC (9.75%), FMR LLC (9.72%), Vanguard Group Inc. (5.86%), Jennison Associates LLC (3.22%) and State Street Corp (3.02%). Company insiders that own Epizyme stock include Andrew E Singer, Bay City Capital Fund V Co-Inv, David M Mott, Peter Tai-Ching Ho, Robert A Copeland and Robert J Gould. View Institutional Ownership Trends for Epizyme.

Epizyme's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., Tekla Capital Management LLC, Jennison Associates LLC, JPMorgan Chase & Co., Schwab Charles Investment Management Inc., California State Teachers Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Epizyme stock in the last year include Andrew E Singer, Peter Tai-Ching Ho and Robert A Copeland. View Insider Buying and Selling for Epizyme.

Epizyme's stock was acquired by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, State Street Corp, Bain Capital Public Equity Management LLC, Vanguard Group Inc., OxFORD Asset Management LLP, Federated Investors Inc. PA, Voya Investment Management LLC and TIAA CREF Investment Management LLC. Company insiders that have bought Epizyme stock in the last two years include Bay City Capital Fund V Co-Inv, David M Mott and Peter Tai-Ching Ho. View Insider Buying and Selling for Epizyme.

Shares of Epizyme can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Epizyme stock can currently be purchased for approximately $15.30.